P
US6893639B2ExpiredUtilityPatentIndex 86

Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates

Assignee: HEMACARE CORPPriority: Oct 19, 2001Filed: Oct 19, 2001Granted: May 17, 2005
Est. expiryOct 19, 2021(expired)· nominal 20-yr term from priority
Inventors:LEVY JOSHUAROTHSTEIN FREDSHIMIAEI BAHMAN
C07K 16/065
86
PatentIndex Score
20
Cited by
18
References
38
Claims

Abstract

The method for immune serum globulin purification relates to the purification of immune globulins from blood plasma with a high degree of efficiency and a high rate of recovery. The immune globulin source is Cohn's fraction I+II+III or II+III prepared from plasma or plasma intermediates by precipitation of the paste at pH 5.7 to 5.8 in the presence of 20% ethanol and 80% purified water. A glycine extraction is followed by an anion exchange chromatography column step to achieve a significantly high yield and high purity of the concentrated protein.

Claims

exact text as granted — not AI-modified
1. A method for producing a high yield of purified immune globulins from blood plasma, comprising:
 providing a plasma source containing immune globulins;  
 suspending the immune globulins in an ethanol solution at a volume equivalent to two times that of the plasma source at a temperature in a range of about −4° C. to −6° C.;  
 adjusting the pH of the suspension to about 5.7 to 5.8;  
 incubating the suspension for at least two hours;  
 adding a volume of a solution of about 2.4M glycine in about 7% ethanol and purified water (volume/volume) equivalent to the volume of the plasma source to the suspension;  
 adjusting the pH of the suspension to about 5.2 to 5.4;  
 extracting the immune globulins from the suspension in a liquid phase to provide an extract containing immune globulins;  
 concentrating the extract containing immune globulins by ultrafiltration of the extract containing immune globulins to provide an immune globulin solution of approximately 1.0 gram/deciliter immune globulins content;  
 performing solvent-exchange on the immune globulin solution with a sodium phosphate solution to provide an extract solution containing immune globulins;  
 removing any impurities from the extract solution containing immune globulins using an anion exchange chromatography column to provide a purified extract solution containing immune globulins;  
 concentrating the purified extract solution containing immune globulins deriving from an effluent of the anion exchange chromatography column by ultrafiltration to provide a concentrated purified extract solution containing immune globulins;  
 inactivating viruses present in the concentrated purified extract solution containing immune globulins;  
 passing the concentrated purified extract solution containing immune globulins through a column containing C-18 resin for removal by adsorption of any residue in the concentrated purified extract solution containing immune globulins from the step of inactivating viruses, wherein the ratio of immune globulins load volume to resin volume is approximately eight parts load volume to one part C-18 resin; and  
 formulating the concentrated purified extract solution containing immune globulins for final use.  
 
     
     
       2. The method of  claim 1 , wherein the plasma source containing immune globulins is selected from the group consisting of a Cohn fraction II+III and a Cohn fraction I+II+III. 
     
     
       3. The method of  claim 1 , wherein the ethanol solution is comprised of about 19% ethanol and about 81% purified water adjusted to a pH of 5.7 to 5.8. 
     
     
       4. The method of  claim 1 , wherein the step of suspending the immune globulins in the ethanol solution comprises vigorously agitating the plasma source. 
     
     
       5. The method of  claim 1 , wherein the step of suspending the immune globulins in the ethanol solution occurs at a temperature of about −5° C. 
     
     
       6. The method of  claim 1 , wherein the plasma source containing immune globulins is derived from human blood plasma. 
     
     
       7. The method of  claim 1 , wherein the plasma source containing immune globulins is derived from a non-human source. 
     
     
       8. The method of  claim 1 , wherein the volume of the immune globulins suspension increases to a volume equivalent to three times that of the plasma source to enhance protein recovery. 
     
     
       9. The method of  claim 1 , wherein the plasma source contains phospholipids. 
     
     
       10. The method of  claim 9 , wherein step of adjusting the pH of the suspension comprises adding 1M sodium acetate to effect precipitation of a majority of the phospholipids as the suspension is continuously agitated. 
     
     
       11. The method of  claim 9 , wherein the step of adjusting the pH of the suspension comprises adding 4M sodium acetate to effect precipitation of a majority of the phospholipids as the suspension is continuously agitated. 
     
     
       12. The method of  claim 1 , wherein the step of incubating the suspension for at least two hours comprises moderately agitating the suspension. 
     
     
       13. The method of  claim 1 , wherein the step of adding the solution of glycine and ethanol to the suspension comprises vigorously mixing the suspension. 
     
     
       14. The method of  claim 1 , wherein the step of adding the solution of glycine and ethanol to the suspension comprises producing a final concentration of glycine in the suspension of about 0.8M and a final concentration of ethanol in the suspension of about 15% (volume/volume). 
     
     
       15. The method of  claim 1 , wherein the step of adjusting the pH of the suspension to about 5.2 to 5.4 further comprises increasing the suspension temperature to approximately −2° C. to −3° C. 
     
     
       16. The method of  claim 1 , wherein the step of extracting the immune globulins from the suspension is performed by one of centrifugation and filtration. 
     
     
       17. The method of  claim 1 , wherein the step of extracting the immune globulins from the suspension is performed by use of a filter press. 
     
     
       18. The method of  claim 1 , wherein the step of extracting the immune globulins from the suspension is facilitated using diatomaceous earth at a concentration of about 1% to about 3% weight by volume during filtration. 
     
     
       19. The method of  claim 1 , wherein the step of extracting the immune globulins from the suspension is performed at a temperature in a range of about −2° C. to −3° C. while moderately agitating the suspension. 
     
     
       20. The method of  claim 1 , wherein the extract containing immune globulins is concentrated by ultrafiltration at a temperature in a range of about −2° C. to −3° C. while moderately agitating the extract containing immune globulins. 
     
     
       21. The method of  claim 1 , wherein the extract containing immune globulins is concentrated through an ultrafilter membrane having a molecular weight cut off of about 100,000. 
     
     
       22. The method of  claim 1 , wherein the step of performing solvent-exchange is performed using a solution of about 20 mM sodium phosphate at a temperature of about 5° C. and a pH of about 6.5. 
     
     
       23. The method of  claim 1 , wherein the step of performing solvent-exchange is performed using a solution of sodium phosphate prepared by mixing sodium phosphate monobasic and sodium phosphate dibasic at a ratio that yields a pH of about 6.5. 
     
     
       24. The method of  claim 1 , wherein the step of performing solvent-exchange is performed using a solution of about 20 mM sodium acetate at a pH of about 6.5. 
     
     
       25. The method of  claim 1 , wherein the step of performing solvent-exchange is performed by addition of one volume of the pH 6.5 buffer to the immune globulins solution forming the extract solution containing immune globulins and concentrating the extract solution containing immune globulins to its original volume. 
     
     
       26. The method of  claim 1 , wherein the step of performing solvent-exchange is performed approximately four times to reduce the alcohol and glycine content. 
     
     
       27. The method of  claim 26 , further comprising increasing the temperature of the immune globulins solution to room temperature at 15° C. to 25° C. after approximately the fourth solvent-exchange. 
     
     
       28. The method of  claim 1 , wherein the anion exchange chromatography column is equilibrated with a 20 mM sodium phosphate buffer at a pH of about 6.5. 
     
     
       29. The method of  claim 28 , wherein the anion exchange chromatography column is washed with at least one column volume of the 20 mM buffer after passing the extract solution containing immune globulins therethrough to obtain further immune globulins recovery. 
     
     
       30. The method of  claim 1 , wherein the anion exchange chromatography column is packed with a gel, and a ratio of immune globulins to the gel is approximately 0.4 grams of protein/milliliter of gel. 
     
     
       31. The method of  claim 1 , wherein the purified extract solution containing immune globulins is concentrated from the column effluent to approximately 6 grams/deciliter immune globulins using an ultrafilter membrane having a molecular weight cut off of about 100,000. 
     
     
       32. The method of  claim 1 , wherein a solvent-detergent method is used for inactivating viruses present in the concentrated purified extract solution containing immune globulins. 
     
     
       33. The method of  claim 32 , wherein a mixture of the purified extract solution containing immune globulins and solvent-detergent yields a final concentration of 0.3% TNBP (tri-n-butyl phosphate) and 1.0% Triton-X-100 and is incubated for about four hours at about 30° C. 
     
     
       34. The method of  claim 1 , wherein the step of passing the concentrated purified extract solution containing immune globulins through a column containing C-18 resin for removal of remaining residue further comprises adjusting the pH of the concentrated purified extract solution containing immune globulins to about 4.6 to about 5.0 with a 4.0M sodium acetate buffer. 
     
     
       35. The method of  claim 1 , wherein the column containing the C-18 resin is equilibrated with a 20 mM sodium acetate buffer at a pH of about 4.6 to about 5.0. 
     
     
       36. The method of  claim 1 , wherein the concentrated purified extract solution containing immune globulins is formulated for final use in one of a liquid and a freeze-dried preparation. 
     
     
       37. The method of  claim 36 , wherein the concentrated purified extract solution containing immune globulins is a liquid preparation with a formulation wherein the concentration of the immune globulins is adjusted to a range of about 5.0 to about 10.0 grams/deciliter protein, 0.1% polysorbate-80 (Tween-80), 0.2M glycine, and pH in a range of about 8.2 to about 8.6. 
     
     
       38. A method for producing a high yield of purified immune globulins from blood plasma, comprising:
 providing a plasma source containing immune globulins;  
 suspending the immune globulins in an ethanol solution at a volume equivalent to two times that of the plasma source at a temperature in a range of about −4° C. to −6° C.;  
 adjusting the pH of the suspension to about 5.7 to 5.8;  
 adding a volume of a solution of about 2.4M glycine in about 7% ethanol and purified water (volume/volume) equivalent to the volume of the plasma source to the suspension;  
 extracting the immune globulins from the suspension in a liquid phase to provide an extract containing immune globulins;  
 concentrating the extract containing immune globulins to provide an immune globulin solution of approximately 1.0 gram/deciliter immune globulins content;  
 performing solvent-exchange on the immune globulin solution with a sodium phosphate solution to provide an extract solution containing immune globulins;  
 removing impurities from the extract solution containing immune globulins using an anion exchange chromatography column to provide a purified extract solution containing immune globulins;  
 concentrating the purified extract solution containing immune globulins deriving from an effluent of the anion exchange chromatography column to provide a concentrated purified extract solution containing immune globulins to provide a concentrated purified extract solution containing immune globulins;  
 inactivating viruses present in the concentrated purified extract solution containing immune globulins;  
 passing the concentrated purified extract solution containing immune globulins through a column containing C-18 resin for removal by adsorption of any residue in the concentrated purified extract solution containing immune globulins from the step of inactivating viruses, wherein the ratio of immune globulins load volume to resin volume is approximately eight parts load volume to one part C-18 resin; and  
 formulating the concentrated purified extract solution containing immune globulins for final use.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.